2. Search Result
Search Result
Results for "

bladder carcinoma

" in MedChemExpress (MCE) Product Catalog:

32

Inhibitors & Agonists

1

Peptides

2

Inhibitory Antibodies

3

Natural
Products

3

Isotope-Labeled Compounds

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-17386
    Rosiglitazone
    Maximum Cited Publications
    175 Publications Verification

    BRL 49653

    		 PPAR TRP Channel Autophagy Ferroptosis Apoptosis Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Rosiglitazone (BRL 49653) is an orally active selective PPARγ agonist (EC50: 60 nM, Kd: 40 nM), with blood-brain barrier permeability. Rosiglitazone is an TRPC5 activator (EC50: 30 μM) and TRPM3 inhibitor. Rosiglitazone can be used in the research of obesity and diabetes, senescence, ovarian cancer .
    Rosiglitazone
  • HY-B1247
    Protoporphyrin IX
    20+ Cited Publications

    PPIX

    		 Endogenous Metabolite Others
    Protoporphyrin IX is a final intermediate in the heme biosynthetic pathway, which acts as a radiation sensitizer enhancing ROS generation even in a hypoxic state and inducing DNA damage. Protoporphyrin IX also acts as a photo sensitizer undergoing photobleaching that occurs through direct degradation by light irradiation. Protoporphyrin IX is formed and accumulated following 5-aminolevulinic acid (5-ALA) (HY-W000450) administration in the tumor cells of rats. Protoporphyrin IX causes selective improvement of basal cell carcinoma when activated red fluorescence of a peak wavelength at 405 nm. Protoporphyrin IX is promising for research of sonodynamic and photodynamic agents for a wide range of cancers, such as bladder cancer and nodular basal cell carcinoma .
    Protoporphyrin IX
  • HY-B0567
    Dequalinium Chloride

    		Potassium Channel nAChR Apoptosis Bacterial Parasite Infection Cancer
    Dequalinium chloride is an Apamin (HY-P0256)-sensitive potassium channel selective blocker. Dequalinium chloride is a cationic, lipophilic mitochondrial poison. Dequalinium chloride is also an antagonist pf α7 nAChR, and an anti-microbial antiseptic agent with a broad bactericidal and fungicidal activity .
    Dequalinium Chloride
  • HY-17386A
    Rosiglitazone hydrochloride
    Maximum Cited Publications
    175 Publications Verification

    BRL 49653 hydrochloride

    		 PPAR TRP Channel Autophagy Ferroptosis Apoptosis Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Rosiglitazone (BRL 49653) hydrochloride is an orally active selective PPARγ agonist (EC50: 60 nM, Kd: 40 nM). Rosiglitazone hydrochloride is a TRPC5 activator (EC50: 30 μM) and TRPM3 inhibitor. Rosiglitazone hydrochloride can be used in the research of obesity and diabetes, senescence, ovarian cancer .
    Rosiglitazone hydrochloride
  • HY-159642
    Dabogratinib

    TYRA-300

    		 FGFR ERK Metabolic Disease Cancer
    Dabogratinib (TYRA-300) is an orally active, selective FGFR3 inhibitor with an IC50 of 11 nM. Dabogratinib exhibits antitumor activity against urothelial carcinoma and solid tumors. Dabogratinib downregulates the FGFR3 and ERK1/2 signaling pathways, and induces tumor growth inhibition and regression in FGFR3-altered xenograft models. Dabogratinib promotes chondrocyte proliferation and differentiation, drives endochondral bone formation and overall body growth, partially restores long bone proportions, and improves craniofacial and spinal morphology. Dabogratinib can be used for the research of metastatic urothelial carcinoma, achondroplasia and hypochondroplasia .
    Dabogratinib
  • HY-149136
    MORF-627

    		Integrin TGF-beta/Smad Inflammation/Immunology
    MORF-627 is a highly selective, orally active integrin αvβ6 inhibitor. By blocking TGF-β1 activation and pSMAD2 signaling, MORF-627 significantly reduces collagen deposition, epithelial-mesenchymal transition markers, and structural changes in fibrotic cells. MORF-627 exhibits significant antifibrotic efficacy without genotoxicity in idiopathic pulmonary fibrosis models. However, MORF-627 induces bladder epithelial proliferation and early invasive urothelial carcinoma in cynomolgus monkeys and human cells, and this toxic effect can be reversed by exogenous TGF-β. MORF-627 can be used for studying the pathological mechanisms of pulmonary fibrosis and evaluating drug safety .
    MORF-627
  • HY-119198
    NSC745885

    		Apoptosis Histone Methyltransferase Cancer
    NSC745885 an effective anti-tumor agent, shows selective toxicity against multiple cancer cell lines but not normal cells. NSC745885 is an effective down-regulator of EZH2 via proteasome-mediated degradation. NSC745885 provides possibilities for the study of advanced bladder and oral squamous cell carcinoma (OSCC) cancers .
    NSC745885
  • HY-110353
    CU-T12-9
    10+ Cited Publications

    		 Toll-like Receptor (TLR) Inflammation/Immunology Cancer
    CU-T12-9 is a specific TLR1/2 agonist with EC50 of 52.9 nM in HEK-Blue hTLR2 SEAP assay. CU-T12-9 activates both the innate and the adaptive immune systems. CU-T12-9 selectively activates the TLR1/2 heterodimer, not TLR2/6. CU-T12-9 signals through NF-κB and invokes an elevation of the downstream effectors TNF-α, IL-10, and iNOS .
    CU-T12-9
  • HY-B1247R
    Protoporphyrin IX (Standard)

    PPIX (Standard)

    		 Reference Standards Endogenous Metabolite Others
    Protoporphyrin IX (Standard) is the analytical standard of Protoporphyrin IX. This product is intended for research and analytical applications. Protoporphyrin IX is a final intermediate in the heme biosynthetic pathway, which acts as a radiation sensitizer enhancing ROS generation even in a hypoxic state and inducing DNA damage. Protoporphyrin IX also acts as a photo sensitizer undergoing photobleaching that occurs through direct degradation by light irradiation. Protoporphyrin IX is formed and accumulated following 5-aminolevulinic acid (5-ALA) (HY-W000450) administration in the tumor cells of rats. Protoporphyrin IX causes selective improvement of basal cell carcinoma when activated red fluorescence of a peak wavelength at 405 nm. Protoporphyrin IX is promising for research of sonodynamic and photodynamic agents for a wide range of cancers, such as bladder cancer and nodular basal cell carcinoma .
    Protoporphyrin IX (Standard)
  • HY-107020
    BMS 310705

    21-Aminoepothilone B

    		 Apoptosis Cancer
    BMS 310705 (21-Aminoepothilone B) is an analog of Epothilone B (HY-17029), targeting to malignancies such as ovarian, renal, bladder, and lung carcinoma. BMS 310705 induces significant apoptosis via mitochondrial-mediated pathway .
    BMS 310705
  • HY-17386R
    Rosiglitazone (Standard)

    BRL 49653 (Standard)

    		 Reference Standards PPAR TRP Channel Autophagy Ferroptosis Apoptosis Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Rosiglitazone (Standard) is the analytical standard of Rosiglitazone. This product is intended for research and analytical applications. Rosiglitazone (BRL 49653) is an orally active selective PPARγ agonist (EC50: 60 nM, Kd: 40 nM). Rosiglitazone is an TRPC5 activator (EC50: 30 μM) and TRPM3 inhibitor. Rosiglitazone can be used in the research of obesity and diabetes, senescence, ovarian cancer .
    Rosiglitazone (Standard)
  • HY-148413
    Aprinocarsen sodium
    1 Publications Verification

    ISIS 3521 sodium

    		 PKC Cancer
    Aprinocarsen (ISIS 3521) sodium, a specific antisense oligonucleotide inhibitor of protein kinase C-alpha (PKC-α). Aprinocarsen sodium is a 20-mer oligonucleotide, it regulates cell differentiation and proliferation. Aprinocarsen sodium inhibits the growth of human tumor cell lines in nude mice. Aprinocarsen sodium shows the value as a chemotherapeutic compound of human cancers .
    Aprinocarsen sodium
  • HY-17386S1
    Rosiglitazone-d4

    BRL 49653-d4

    		 TRP Channel Autophagy PPAR Ferroptosis Apoptosis Isotope-Labeled Compounds Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Rosiglitazone-d4 is deuterated labeled Rosiglitazone (HY-17386). Rosiglitazone (BRL 49653) is an orally active selective PPARγ agonist (EC50: 60 nM, Kd: 40 nM). Rosiglitazone is an TRPC5 activator (EC50: 30 μM) and TRPM3 inhibitor. Rosiglitazone can be used in the research of obesity and diabetes, senescence, ovarian cancer .
    Rosiglitazone-d4
  • HY-B1247A
    Protoporphyrin IX disodium
    20+ Cited Publications

    PPIX disodium

    		 Endogenous Metabolite Cancer
    Protoporphyrin IX disodium is a final intermediate in the heme biosynthetic pathway, which acts as a radiation sensitizer enhancing ROS generation even in a hypoxic state and inducing DNA damage. Protoporphyrin IX disodium also acts as a photo sensitizer undergoing photobleaching that occurs through direct degradation by light irradiation. Protoporphyrin IX disodium is formed and accumulated following 5-aminolevulinic acid (5-ALA) (HY-W000450) administration in the tumor cells of rats. Protoporphyrin IX disodium causes selective improvement of basal cell carcinoma when activated red fluorescence of a peak wavelength at 405 nm. Protoporphyrin IX disodium is promising for research of sonodynamic and photodynamic agents for a wide range of cancers, such as bladder cancer and nodular basal cell carcinoma .
    Protoporphyrin IX disodium
  • HY-17509
    Deracoxib
    1 Publications Verification

    SC 046; SC 46; SC 59046

    		 COX Apoptosis Neurological Disease Inflammation/Immunology Cancer
    Deracoxib (SC 046; SC 59046), an orally active COX-2 inhibitor, is a veterinary nonsteroidal anti-inflammatory agent used exclusively in dogs. Deracoxib inhibits the COX-2 enzyme to reduce the production of prostaglandins, effectively controlling pain and inflammation after canine soft tissue surgery. Deracoxib reduces the inhibition of COX-1 and lowers the risk of gastrointestinal side effects. Deracoxib induces tumor cell cycle arrest and apoptosis, and shows anti-tumor activity in canine osteosarcoma, breast tumors and bladder transitional cell carcinomas .
    Deracoxib
  • HY-17509S
    Deracoxib-d3

    SC 046-d3; SC 46-d3; SC 59046-d3

    		 Isotope-Labeled Compounds COX Apoptosis Neurological Disease Inflammation/Immunology Cancer
    Deracoxib-d3 (SC 046-d3; SC 59046-d3) is the deuterium labeled Deracoxib (HY-17509). Deracoxib, an orally active COX-2 inhibitor, is a veterinary nonsteroidal anti-inflammatory agent used exclusively in dogs. Deracoxib inhibits the COX-2 enzyme to reduce the production of prostaglandins, effectively controlling pain and inflammation after canine soft tissue surgery. Deracoxib reduces the inhibition of COX-1 and lowers the risk of gastrointestinal side effects. Deracoxib induces tumor cell cycle arrest and apoptosis, and shows anti-tumor activity in canine osteosarcoma, breast tumors and bladder transitional cell carcinomas.
    Deracoxib-d3
  • HY-174981
    LC-MF-4

    		PROTACs FGFR ATP Synthase Cancer
    LC-MF-4 is a selective FGFR3 PROTAC degrader with a DC50 of 30.89 nM in KMS-11 cells. LC-MF-4 inhibits the metabolic function of FGFR3-TACC3 fusion positive cancers with reduction of ATP synthesis and inhibition of mitochondrial biogenesis genes. LC-MF-4 has potent antitumor activity in the Ba/F3-FGFR3-TACC3 xenograft mice model. LC-MF-4 can be used for FGFR3-altered cancers like bladder cancer and urothelial carcinoma (UC) research . Pink: FGFR3 ligand (HY-175414); Blue: VHL ligase ligand (HY-125905); Black: linker (HY-Y1224)
    LC-MF-4
  • HY-B0567R
    Dequalinium Chloride (Standard)

    		Reference Standards Potassium Channel nAChR Apoptosis Bacterial Parasite Infection Cancer
    Dequalinium (Chloride) (Standard) is the analytical standard of Dequalinium (Chloride). This product is intended for research and analytical applications. Dequalinium chloride is an Apamin (HY-P0256)-sensitive potassium channel selective blocker. Dequalinium chloride is a cationic, lipophilic mitochondrial poison. Dequalinium chloride is also an antagonist pf α7 nAChR, and an anti-microbial antiseptic agent with a broad bactericidal and fungicidal activity .
    Dequalinium Chloride (Standard)
  • HY-17386B
    Rosiglitazone potassium
    170+ Cited Publications

    BRL 49653 potassium

    		 PPAR TRP Channel Autophagy Apoptosis Ferroptosis Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Rosiglitazone (BRL 49653) potassium is an orally active selective PPARγ agonist (EC50: 60 nM, Kd: 40 nM). Rosiglitazone potassium is a TRPC5 activator (EC50: 30 μM) and TRPM3 inhibitor. Rosiglitazone potassium can be used in the research of obesity and diabetes, senescence, ovarian cancer .
    Rosiglitazone potassium
  • HY-159085
    P-gp inhibitor 24

    		P-glycoprotein Cancer
    P-gp inhibitor 24 (Compound 10) is an inhibitor for P-glycoprotein (P-gp)), that inhibits the P-gp mediated fluorescent dye efflux. P-gp inhibitor 24 exhibits multidrug resistance (MDR) reversal effect, enhances the cytotoxicity of Vincristine (HY-N0488) and Etoposide (HY-13629) in cancer cells .
    P-gp inhibitor 24
  • HY-W014394R
    Vanillyl butyl ether (Standard)

    		TRP Channel Reference Standards Parasite Cardiovascular Disease
    Protoporphyrin IX (Standard) is the analytical standard of Protoporphyrin IX. This product is intended for research and analytical applications. Protoporphyrin IX is a final intermediate in the heme biosynthetic pathway, which acts as a radiation sensitizer enhancing ROS generation even in a hypoxic state and inducing DNA damage. Protoporphyrin IX also acts as a photo sensitizer undergoing photobleaching that occurs through direct degradation by light irradiation. Protoporphyrin IX is formed and accumulated following 5-aminolevulinic acid (5-ALA) (HY-W000450) administration in the tumor cells of rats. Protoporphyrin IX causes selective improvement of basal cell carcinoma when activated red fluorescence of a peak wavelength at 405 nm. Protoporphyrin IX is promising for research of sonodynamic and photodynamic agents for a wide range of cancers, such as bladder cancer and nodular basal cell carcinoma .
    Vanillyl butyl ether (Standard)
  • HY-17509R
    Deracoxib (Standard)

    SC 046 (Standard); SC 46 (Standard); SC 59046 (Standard)

    		 Reference Standards COX Apoptosis Neurological Disease Inflammation/Immunology Cancer
    Deracoxib (SC 046; SC 59046) (Standard) is the analytical standard of Deracoxib (HY-17509). This product is intended for research and analytical applications. Deracoxib, an orally active COX-2 inhibitor, is a veterinary nonsteroidal anti-inflammatory agent used exclusively in dogs. Deracoxib inhibits the COX-2 enzyme to reduce the production of prostaglandins, effectively controlling pain and inflammation after canine soft tissue surgery. Deracoxib reduces the inhibition of COX-1 and lowers the risk of gastrointestinal side effects. Deracoxib induces tumor cell cycle arrest and apoptosis, and shows anti-tumor activity in canine osteosarcoma, breast tumors and bladder transitional cell carcinomas
    Deracoxib (Standard)
  • HY-W703540
    Deracoxib-d4

    SC 046-d4; SC 46-d4; SC 59046-d4

    		 Isotope-Labeled Compounds Apoptosis COX Neurological Disease Inflammation/Immunology Cancer
    Deracoxib-d4 (SC 046-d4; SC 59046--d4) is deuterium labeled Deracoxib (HY-17509). Deracoxib, an orally active COX-2 inhibitor, is a veterinary nonsteroidal anti-inflammatory agent used exclusively in dogs. Deracoxib inhibits the COX-2 enzyme to reduce the production of prostaglandins, effectively controlling pain and inflammation after canine soft tissue surgery. Deracoxib reduces the inhibition of COX-1 and lowers the risk of gastrointestinal side effects. Deracoxib induces tumor cell cycle arrest and apoptosis, and shows anti-tumor activity in canine osteosarcoma, breast tumors and bladder transitional cell carcinomas.
    Deracoxib-d4
  • HY-17386AR
    Rosiglitazone hydrochloride (Standard)

    BRL 49653 hydrochloride (Standard)

    		 PPAR TRP Channel Autophagy Ferroptosis Apoptosis Reference Standards Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Rosiglitazone (hydrochloride) (Standard) is the analytical standard of Rosiglitazone (hydrochloride). This product is intended for research and analytical applications. Rosiglitazone (BRL 49653) hydrochloride is an orally active selective PPARγ agonist (EC50: 60 nM, Kd: 40 nM). Rosiglitazone hydrochloride is a TRPC5 activator (EC50: 30 μM) and TRPM3 inhibitor. Rosiglitazone hydrochloride can be used in the research of obesity and diabetes, senescence, ovarian cancer .
    Rosiglitazone hydrochloride (Standard)
  • HY-W409652
    CLK1/4-IN-2

    		CDK EGFR HDAC Cancer
    CLK1/4-IN-2 is a selective CLK1/4 inhibitor, with an IC50 of 7 nM against CLK1 and an IC50 of 2.3 nM against CLK4. CLK1/4-IN-2 induces protein depletion in cancer cells and exhibits anticancer activity. CLK1/4-IN-2 can be used in research related to breast cancer, monocytic leukemia, bladder cancer, mammary adenocarcinoma and hepatocellular carcinoma .
    CLK1/4-IN-2
  • HY-181271
    IKKε-IN-1

    		IKK Autophagy Cancer
    IKKε-IN-1 is a IKKε inhibitor. IKKε-IN-1 reduces cell viability, inhibits colony formation and cell migration. IKKε-IN-1 induces autophagy (Autophagy) in cancer cells. IKKε-IN-1 can be used in the research of cancers including colorectal cancer, hepatocellular carcinoma, bladder cancer, breast cancer, lung cancer, and cervical cancer .
    IKKε-IN-1
  • HY-181752
    FGFR3-IN-12

    		FGFR TNK1 Apoptosis Caspase Cancer
    FGFR3-IN-12 is a selective fibroblast growth factor receptor 3 (FGFR3) inhibitor with an IC50 of 6.8 nM. FGFR3-IN-12 shows an IC50 of 19.2 nM against FGFR3 V555M and an IC50 of 16.9 nM against TNK1 (Thirty-eight Negative Kinase 1). FGFR3-IN-12 inhibits cancer cells proliferation and induces caspase-mediated apoptosis. FGFR3-IN-12 exhibits antitumor activity in bladder cancer xenografts mice models. FGFR3-IN-12 can be used for the research of cancer, such as bladder cancer .
    FGFR3-IN-12
  • HY-182747
    HDAC6-IN-79

    		HDAC Autophagy Apoptosis Cancer
    HDAC6-IN-79 is a HDAC6 inhibitor with an IC50 of 98.40 nM, and it also exhibits inhibitory activity against other HDAC subtypes (HDAC1: 639.0 nM, HDAC2: 798.9 nM, HDAC8: 865.7 nM, HDAC4: 1187 nM). HDAC6-IN-79 induces acetylation of α-tubulin and histone H3, reduces the viability of cancer cells, activates the autophagy pathway and induces apoptosis. HDAC6-IN-79 can be used for research related to urothelial carcinoma (bladder cancer) .
    HDAC6-IN-79
  • HY-E70718
    FGFR3 G697C Recombinant Human Active Protein Kinase

    		FGFR Cancer
    FGFR3 activating mutations are drivers of malignancy in several human tissues, including bladder, lung, cervix, and blood. FGFR3 G697C is a mutant of FGFR3 that may be present in oral squamous cell carcinoma. FGFR3 G697C increases FGFR3 auto-phosphorylation. FGFR3 G697C Recombinant Human Active Protein Kinase is a recombinant FGFR3 G697C protein that can be used to study FGFR3 G697C-related functions .
    FGFR3 G697C Recombinant Human Active Protein Kinase
  • HY-P992361
    HB0030

    		Transmembrane Glycoprotein Cancer
    HB0030 is a TIGIT inhibitor with antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) activities. HB0030 enhances the expression of activation markers in natural killer (NK) cells, promotes the killing of regulatory T cells (Tregs), and reduces the proportion of FoxP3 + Treg in tumor-infiltrating lymphocytes. The combination of HB0030 with the anti-PD-L1/VEGF bispecific antibody HB0025 further enhances tumor suppression efficacy. HB0030 can be used in studies related to colorectal cancer, pancreatic adenocarcinoma, hepatocellular carcinoma, bladder cancer, breast cancer, non-small cell lung cancer, and advanced solid tumors .
    HB0030
  • HY-181567
    METTL3-IN-13

    		METTL3 Cancer
    METTL3-IN-13 is a METTL3 inhibitor. METTL3-IN-13 is applicable to the research of multiple cancers such as hypopharyngeal squamous cell carcinoma and non-small cell lung cancer .
    METTL3-IN-13
  • HY-P992413
    MOR102

    		Integrin Inflammation/Immunology
    MOR102 is a fully human IgG4 monoclonal antibody and an ICAM-1 inhibitor, lacking cross-reactivity with ICAM-2 and ICAM-3. MOR102 binds to the LFA-1 binding site within ICAM-1 domain 1, blocks ICAM-1/LFA-1 interaction, binds human keratinocytes with increased binding to interferon-γ-stimulated keratinocytes. MOR102 inhibits lymphocyte adhesion, reduces lymphocyte proliferation, prevents local T-cell activation, reduces inflammatory infiltrate, restores orthokeratotic differentiation, and reduces epidermal thickness. MOR102 can be used for the research of psoriasis .
    MOR102

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: